Tumor Biology

, Volume 36, Issue 11, pp 8447–8453 | Cite as

Prognostic significance of Nemo-like kinase expression in patients with hepatocellular carcinoma

  • Hong-Wei Chen
  • Hong-Ying Qiao
  • Hong-Chen Li
  • Zong-Feng Li
  • Hong-Juan Zhang
  • Liu Pei
  • Hong-Wei Liu
  • Liang Jin
  • Dong Wang
  • Jun-Liang Li
Research Article


Nemo-like kinase (NLK) is an evolutionarily conserved serine/threonine protein kinase and belongs to the extracellular signal-regulated kinases/microtubule-associated protein kinase families (Erks/MAPKs). Previous studies have indicated that abnormal expressions of NLK played critical roles in various types of human cancers. Recent studies suggested that NLK expression was significantly upregulated in the hepatocellular carcinoma (HCC) specimens. However, the clinical significance of NLK expression in HCC remains largely unknown. In this study, we focused on the clinical significance of NLK in HCC and found that high expression of NLK was significantly associated with Edmondson–Steiner grade (P = 0.002), tumor size (P = 0.022), and no. of tumor nodules (P < 0.001), and NLK was positively correlated with proliferation marker Ki-67 (P < 0.01). Univariate analysis suggested that NLK expression was associated with poor prognosis (P < 0.001). Multivariate analysis indicated that NLK expression was an independent prognostic indicator for HCC (P = 0.0370). In conclusion, NLK overexpression is associated with poor overall survival in patients with HCC, it might be an independent poor prognostic marker for HCC.


Hepatocellular carcinoma Nemo-like kinase Immunohistochemistry Prognostic significance 



We would like to acknowledge the reviewers for their helpful comments on this paper. We would also like to thank our colleagues at the Department of Clinical Laboratory, the First Hospital of Qinhuangdao.

Conflicts of interest



  1. 1.
    Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907–17.CrossRefPubMedGoogle Scholar
  2. 2.
    Munoz A, Chen JG, Egner PA, Marshall ML, Johnson JL, Schneider MF, et al. Predictive power of hepatitis b 1762T/1764A mutations in plasma for hepatocellular carcinoma risk in Qidong, China. Carcinogenesis. 2011;32:860–5.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–76.CrossRefPubMedGoogle Scholar
  4. 4.
    Wang XM, Yang LY, Guo L, Fan C, Wu F. p53-induced RING-H2 protein, a novel marker for poor survival in hepatocellular carcinoma after hepatic resection. Cancer. 2009;115:4554–63.CrossRefPubMedGoogle Scholar
  5. 5.
    Lv L, Wan C, Chen B, Li M, Liu Y, Ni T, et al. Nemo-like kinase (NLK) inhibits the progression of NSCLC via negatively modulating WNT signaling pathway. J Cell Biochem. 2014;115:81–92.CrossRefPubMedGoogle Scholar
  6. 6.
    Mendes-Pereira AM, Lord CJ, Ashworth A. NLK is a novel therapeutic target for PTEN deficient tumour cells. PLoS One. 2012;7, e47249.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Li Z, Cui G, Wang J, Yu Z, Zhao L, Lv Z. Nemo-like kinase (NLK) involves in neuronal apoptosis after traumatic brain injury. Cell Mol Neurobiol. 2012;32:381–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Ota S, Ishitani S, Shimizu N, Matsumoto K, Itoh M, Ishitani T. NLK positively regulates Wnt/beta-catenin signalling by phosphorylating lef1 in neural progenitor cells. EMBO J. 2012;31:1904–15.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Yasuda J, Tsuchiya A, Yamada T, Sakamoto M, Sekiya T, Hirohashi S. Nemo-like kinase induces apoptosis in DLD-1 human colon cancer cells. Biochem Biophys Res Commun. 2003;308:227–33.CrossRefPubMedGoogle Scholar
  10. 10.
    Tan Z, Li M, Wu W, Zhang L, Ding Q, Wu X, et al. NLK is a key regulator of proliferation and migration in gallbladder carcinoma cells. Mol Cell Biochem. 2012;369:27–33.CrossRefPubMedGoogle Scholar
  11. 11.
    Li M, Zhang S, Wang Z, Zhang B, Wu X, Weng H, et al. Prognostic significance of nemo-like kinase (NLK) expression in patients with gallbladder cancer. Tumour Biol. 2013;34:3995–4000.CrossRefPubMedGoogle Scholar
  12. 12.
    Jung KH, Kim JK, Noh JH, Eun JW, Bae HJ, Xie HJ, et al. Targeted disruption of Nemo-like kinase inhibits tumor cell growth by simultaneous suppression of cyclin D1 and CDK2 in human hepatocellular carcinoma. J Cell Biochem. 2010;110:687–96.CrossRefPubMedGoogle Scholar
  13. 13.
    Zhou L, Rui JA, Ye DX, Wang SB, Chen SG, Qu Q. Edmondson-Steiner grading increases the predictive efficiency of TNM staging for long-term survival of patients with hepatocellular carcinoma after curative resection. World J Surg. 2008;32:1748–56.CrossRefPubMedGoogle Scholar
  14. 14.
    Woelfle U, Cloos J, Sauter G, Riethdorf L, Janicke F, van Diest P, et al. Molecular signature associated with bone marrow micrometastasis in human breast cancer. Cancer Res. 2003;63:5679–84.PubMedGoogle Scholar
  15. 15.
    Li X, Pan Y, Fan R, Jin H, Han S, Liu J, et al. Adenovirus-delivered ciapin1 small interfering RNA inhibits HCC growth in vitro and in vivo. Carcinogenesis. 2008;29:1587–93.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Han Y, Kuang Y, Xue X, Guo X, Li P, Wang X, et al. NLK, a novel target of miR-199a-3p, functions as a tumor suppressor in colorectal cancer. Biomed Pharmacother. 2014;68:497–505.CrossRefPubMedGoogle Scholar
  17. 17.
    Emami KH, Brown LG, Pitts TE, Sun X, Vessella RL, Corey E. Nemo-like kinase induces apoptosis and inhibits androgen receptor signaling in prostate cancer cells. Prostate. 2009;69:1481–92.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Cui G, Li Z, Shao B, Zhao L, Zhou Y, Lu T, et al. Clinical and biological significance of nemo-like kinase expression in glioma. J Clin Neurosci. 2011;18:271–5.CrossRefPubMedGoogle Scholar
  19. 19.
    Wang K, Wang X, Zou J, Zhang A, Wan Y, Pu P, et al. miR-92b controls glioma proliferation and invasion through regulating Wnt/beta-catenin signaling via Nemo-like kinase. Neuro Oncol. 2013;15:578–88.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Zhang Y, Peng C, Wu G, Wang Y, Liu R, Yang S, et al. Expression of NLK and its potential effect in ovarian cancer chemotherapy. Int J Gynecol Cancer. 2011;21:1380–7.CrossRefPubMedGoogle Scholar
  21. 21.
    Huang Y, Jiang Y, Lu W, Zhang Y. Nemo-like kinase associated with proliferation and apoptosis by c-Myb degradation in breast cancer. PLoS One. 2013;8, e69148.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Zhang B, Li KY, Chen HY, Pan SD, Chen SF, Zhang WF, et al. Lentivirus-based RNA silencing of Nemo-like kinase (NLK) inhibits the CAL 27 human adenosquamos carcinoma cells proliferation and blocks G0/G1 phase to S phase. Int J Med Sci. 2013;10:1301–6.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Chen S, Ma Z, Chen X, Zhang J. Prognostic significance of nemo-like kinase in nasopharyngeal carcinoma. Mol Med Rep. 2014;10:131–6.PubMedGoogle Scholar
  24. 24.
    Mann CD, Neal CP, Garcea G, Manson MM, Dennison AR, Berry DP. Prognostic molecular markers in hepatocellular carcinoma: a systematic review. Eur J Cancer. 2007;43:979–92.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Hong-Wei Chen
    • 1
  • Hong-Ying Qiao
    • 2
  • Hong-Chen Li
    • 1
  • Zong-Feng Li
    • 1
  • Hong-Juan Zhang
    • 1
  • Liu Pei
    • 1
  • Hong-Wei Liu
    • 1
  • Liang Jin
    • 1
  • Dong Wang
    • 1
  • Jun-Liang Li
    • 1
  1. 1.Department of Clinical LaboratoryThe First Hospital of QinhuangdaoQinhuangdaoChina
  2. 2.Department of AllergyThe First Hospital of QinhuangdaoQinhuangdaoChina

Personalised recommendations